Insider Selling: OmniAb, Inc. (NASDAQ:OABI) Insider Sells 8,215 Shares of Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 8,215 shares of OmniAb stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total value of $30,231.20. Following the completion of the transaction, the insider now directly owns 364,131 shares of the company’s stock, valued at approximately $1,340,002.08. This represents a 2.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

OmniAb Price Performance

Shares of OABI stock opened at $3.88 on Friday. The company’s fifty day moving average price is $3.49 and its 200-day moving average price is $3.91. OmniAb, Inc. has a one year low of $3.10 and a one year high of $6.55. The company has a market capitalization of $547.93 million, a price-to-earnings ratio of -6.26 and a beta of -0.12.

Institutional Investors Weigh In On OmniAb

A number of institutional investors have recently added to or reduced their stakes in the stock. Palumbo Wealth Management LLC grew its stake in OmniAb by 12.5% during the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after acquiring an additional 2,744 shares in the last quarter. Invesco Ltd. increased its stake in OmniAb by 3.3% in the 4th quarter. Invesco Ltd. now owns 93,653 shares of the company’s stock worth $332,000 after acquiring an additional 2,997 shares during the last quarter. Connors Investor Services Inc. increased its stake in OmniAb by 18.4% in the 4th quarter. Connors Investor Services Inc. now owns 29,611 shares of the company’s stock worth $105,000 after acquiring an additional 4,611 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of OmniAb by 16.5% during the 4th quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock valued at $144,000 after acquiring an additional 5,751 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC boosted its position in shares of OmniAb by 53.5% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company’s stock valued at $61,000 after acquiring an additional 6,001 shares during the last quarter. 72.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Benchmark reaffirmed a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of OmniAb in a research report on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.